Shares of Vericel Corp (NASDAQ:VCEL) were up 0.7% during trading on Thursday . The company traded as high as $14.60 and last traded at $13.70. Approximately 53,980 shares changed hands during trading, a decline of 94% from the average daily volume of 838,740 shares. The stock had previously closed at $13.80.
A number of analysts have recently commented on VCEL shares. BidaskClub cut Vericel from a “strong-buy” rating to a “buy” rating in a research report on Friday, June 15th. LADENBURG THALM/SH SH upgraded Vericel from a “neutral” rating to a “buy” rating in a research report on Monday, July 16th. BTIG Research restated a “buy” rating and issued a $17.00 price target on shares of Vericel in a research report on Tuesday, August 7th. Finally, Needham & Company LLC dropped their price target on Vericel from $15.00 to $14.00 and set a “buy” rating on the stock in a research report on Wednesday, August 8th. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. Vericel currently has a consensus rating of “Buy” and an average price target of $15.00.
The stock has a market cap of $591.76 million, a PE ratio of -26.40 and a beta of 2.99. The company has a quick ratio of 7.48, a current ratio of 7.72 and a debt-to-equity ratio of 0.16.
Vericel (NASDAQ:VCEL) last issued its quarterly earnings results on Monday, August 6th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.12). The firm had revenue of $19.01 million for the quarter, compared to analysts’ expectations of $18.51 million. Vericel had a negative return on equity of 37.86% and a negative net margin of 23.35%. research analysts forecast that Vericel Corp will post -0.36 earnings per share for the current year.
In other Vericel news, Director Paul K. Wotton sold 30,000 shares of the business’s stock in a transaction that occurred on Monday, June 18th. The stock was sold at an average price of $12.06, for a total transaction of $361,800.00. Following the transaction, the director now owns 5,000 shares in the company, valued at approximately $60,300. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Steven C. Gilman sold 9,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 4th. The stock was sold at an average price of $12.03, for a total value of $108,270.00. Following the transaction, the director now owns 9,000 shares in the company, valued at approximately $108,270. The disclosure for this sale can be found here. Insiders own 3.30% of the company’s stock.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Capital Fund Management S.A. acquired a new position in Vericel during the 2nd quarter worth approximately $104,000. Quantitative Systematic Strategies LLC acquired a new position in Vericel during the 2nd quarter worth approximately $108,000. Connor Clark & Lunn Investment Management Ltd. acquired a new position in Vericel during the 2nd quarter worth approximately $116,000. Commonwealth Equity Services LLC acquired a new position in Vericel during the 2nd quarter worth approximately $123,000. Finally, Metropolitan Life Insurance Co. NY acquired a new position in Vericel during the 2nd quarter worth approximately $128,000. Institutional investors own 76.47% of the company’s stock.
About Vericel (NASDAQ:VCEL)
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, markets, and sells patient-specific expanded cellular therapies to repair and regenerate damaged tissues and organs. It markets autologous cell therapy products, including MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Carticel, an autologous chondrocyte implant for the repair of symptomatic cartilage defects of the femoral condyle caused by acute or repetitive trauma in patients that have inadequate response to a prior arthroscopic or other surgical repair procedure.
Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.